<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185679</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-12600</org_study_id>
    <secondary_id>BMT123</secondary_id>
    <secondary_id>NCI-2011-00424</secondary_id>
    <secondary_id>77453</secondary_id>
    <nct_id>NCT00185679</nct_id>
  </id_info>
  <brief_title>Haploid Allogeneic Transplant Using the CliniMACS System</brief_title>
  <official_title>A Feasibility Study Evaluating Haploidentical Allogeneic Transplantation Using the CliniMACS System in Patients With Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ginna Laport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the proportion of patients with donor neutrophil engraftment within 30 days of
      allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the proportion of patients with donor neutrophil engraftment within 30 days of
      allogeneic transplant; assess the incidence of acute GvHD during the first 100 days after
      transplantation; and assess platelet engraftment, graft failure, chronic GvHD, clinical
      safety, and devise performance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was superseded by the subsequent study IRB-15919 (NCT01050764)
  </why_stopped>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>30 days post-transplant</time_frame>
    <description>Number of subjects recovering neutrophils, assessed as 1st of 3 consecutive days on which ANC &gt; 0.5x10e9/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute GvHD (Grade II-IV)</measure>
    <time_frame>within 100 days post-transplant</time_frame>
    <description>Number of subjects with acute GvHD (grade II-IV) within 100 days post-transplant, per the Consensus Conference on Acute GvHD Grading (Przepiorka D, et al. Bone Marrow Transplantation. 1995. 15:825-828).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Recovery</measure>
    <time_frame>40 days</time_frame>
    <description>Number of subjects recovering platelets to &gt; 20x10e9/L, assessed on the 7th day unsupported by platelet transfusions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors</condition>
  <condition>Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase</condition>
  <condition>Myelodysplastic Syndrome (MDS) - High and Intermediate Risk</condition>
  <condition>Non-Hodgkin's Lymphoma (NHL)</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL) - Refractory</condition>
  <arm_group>
    <arm_group_label>Haploidentical Allogeneic Transplant Using CliniMACS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS System</intervention_name>
    <description>The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
    <arm_group_label>Haploidentical Allogeneic Transplant Using CliniMACS System</arm_group_label>
    <other_name>CliniMACS Cell Selection System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        RECIPIENT INCLUSION CRITERIA

        Histopathologically-confirmed diagnosis of hematological or lymphatic malignancy, defined
        as one of the following:

          -  Acute myeloid leukemia (AML) as primary refractory disease, or in relapse

          -  Acute leukemia in first remission with poor risk factors and molecular prognosis

          -  AML with -5,-7, t(6;9), tri8, -11

          -  Acute lymphocytic / lymphoblastic leukemia (ALL) with Phil+ t(9;22),(q34;q11.2), and
             t(4:11)(q21;23)

          -  Chronic myelogenous leukemia (CML in accelerated, second chronic phase

          -  Myelodysplastic syndrome with high intermediate to high risk categories

          -  Non-Hodgkin's lymphoma (NHL)

          -  Chronic lymphocytic leukemia (CLL), Refractory &lt; 50 years old at time of registration
             Donor is related Donor is genotypically-matched and haploidentical for HLA-A, B,C and
             DRB1, DQ loci Donor differs for 2 or 3 HLA alleles on the unshared haplotype in the
             GvHD direction No HLA-matched sibling or matched unrelated donor is identified ECOG
             performance status not more than 2 LVEF &gt; 45% DLCO &gt; 50% corrected for hemoglobin
             Serum creatinine

          -  &lt; 1.5 mg/dL OR

          -  creatinine clearance &gt; 50 mL/min for those above serum creatinine of 1.5 mg/dL serum
             bilirubin &lt; 2.0 mg/dL ALT &lt; 2x ULN (unless secondary to disease) Females of
             childbearing potential must have a negative serum or urine beta-HCG test within 3
             weeks of registration No prior cancer within 5 years with the exception of
             surgically-cured, non-melanoma skin cancer or in situ cancer of the cervix No prior
             myeloablative therapy or transplant Duly-executed informed consent

        RECIPIENT EXCLUSION CRITERIA Suitable candidate for autologous transplantation
        Participation in other investigational drugs or devices trials that might influence the
        study endpoints Evidence of active hepatitis Evidence of active cirrhosis HIV-positive
        History of invasive aspergillosis Presence of any other uncontrolled, active infection, ie,
        bacterial, viral or fungal Uncontrolled CNS involvement Documented allergy to murine
        proteins Documented allergy to iron dextran Lactating female Female of child-bearing
        potential unwilling to implement adequate birth control Medical problem /
        neurologic/psychiatric dysfunction which would impair his/her ability to be compliant with
        the medical regimen and/or to tolerate transplantation, in the opinion of the principal
        investigator Medical problem / neurologic/psychiatric dysfunction which would prolong
        hematologic recovery and place the recipient at unacceptable risk, in the opinion of the
        principal investigator would .

        DONOR INCLUSION CRITERIA Age &lt; 60 years Weight &gt; 25 kg Medical history and physical
        examination confirm good health status as defined by institutional standards Within 30 days
        of apheresis collection, seronegative for HIV assessed as HIV Ag; HIV 1+2 Ab; or HTLV I/II
        Ab Within 30 days of apheresis collection, seronegative for hepatitis assessed as HBsAg;
        HBcAb (IgM and IgG); or HCV Ab Within 30 days of apheresis collection, seronegative for
        syphilis assessed as RPR Genotypically haploidentical as determined by HLA typing Female
        donors of child-bearing potential must have a negative serum or urine beta-HCG test within
        3 weeks of mobilization Capable of undergoing leukapheresis Has adequate venous access
        Willing to undergo insertion of a central catheter should leukapheresis via peripheral vein
        be inadequate Agreeable to second donation of PBPC (or a bone marrow harvest) should the
        recipient fail to demonstrate sustained engraftment following the transplant Duly-executed
        informed consent Screened for CMV seroreactivity

          -  Must be seronegative donor if recipeint is seronegative.

          -  Otherwise the donor will be selected on the ability of NK cell alloreactivity based
             upon HLA typing results and donors who are capable of NK cell alloreactivity will be
             used preferentially.

        DONOR EXCLUSION CRITERIA Evidence of active infection (including urinary tract infection,
        or upper respiratory tract infection) Evidence of hepatitis (on screening) Medical,
        physical or psychological reason which makes the donor unlikely to tolerate or cooperate
        with growth factor therapy and leukapheresis Factors placing donor at increased risk for
        leukapheresis or G-CSF-related complications Lactating female Female of child-bearing
        potential unwilling to implement adequate birth control HIV-positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginna G Laport, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 26, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2015</results_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ginna Laport</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
          <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
          <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="21" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neutrophil Engraftment</title>
        <description>Number of subjects recovering neutrophils, assessed as 1st of 3 consecutive days on which ANC &gt; 0.5x10e9/L</description>
        <time_frame>30 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
            <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Engraftment</title>
          <description>Number of subjects recovering neutrophils, assessed as 1st of 3 consecutive days on which ANC &gt; 0.5x10e9/L</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GvHD (Grade II-IV)</title>
        <description>Number of subjects with acute GvHD (grade II-IV) within 100 days post-transplant, per the Consensus Conference on Acute GvHD Grading (Przepiorka D, et al. Bone Marrow Transplantation. 1995. 15:825-828).</description>
        <time_frame>within 100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
            <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GvHD (Grade II-IV)</title>
          <description>Number of subjects with acute GvHD (grade II-IV) within 100 days post-transplant, per the Consensus Conference on Acute GvHD Grading (Przepiorka D, et al. Bone Marrow Transplantation. 1995. 15:825-828).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Recovery</title>
        <description>Number of subjects recovering platelets to &gt; 20x10e9/L, assessed on the 7th day unsupported by platelet transfusions</description>
        <time_frame>40 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
            <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Recovery</title>
          <description>Number of subjects recovering platelets to &gt; 20x10e9/L, assessed on the 7th day unsupported by platelet transfusions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs reported through Day 100 post-transplant.</time_frame>
      <desc>Non-serious adverse events not reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
          <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS - Other, graft failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, demyelinating ecephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment-related secondary malignancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, pulmonary fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ginna G Laport, MD</name_or_title>
      <organization>Stanford Cancer Institute</organization>
      <phone>650-723-8222 ext 13911</phone>
      <email>ginna.laport@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

